35 results about "Protein precursor" patented technology

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and / or activity.

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and / or activity.

The invention discloses a recombined adenovirus expressing Asia-1 foot-and-mouth disease virus VLP (Virus-like Particles) and application thereof. The recombined adenovirus is obtained by the following steps of: splicing an FMDV (Foot-and-Mouth Disease Virus) capsid protein precursor P1-2A gene and a 3C gene together to obtain a fusion gene, wherein a base sequence of the fusion gene is SEQ ID NO as shown in a table 1; connecting the base sequence of SEQ ID NO as shown in the table 1 with an adenovirus shuttle vector to obtain a recombined adenovirus shuttle vector; and recombining the recombined adenovirus shuttle vector into a human defective adenovirus-5, screening, and identifying to obtain the recombined adenovirus efficiently expressing the Asia-1 foot-and-mouth disease virus VLP, wherein the microbial preservation number of the recombined adenovirus is CGMCC No. 3467. The Asia-1 foot-and-mouth disease virus VLP established by the invention and expressed by a defective adenovirus can continuously induce high-level neutralizing antibodies in mice and can be used as vaccines for preventing Asia-1 foot-and-mouth diseases.

The invention provides a manufacturing method for solving sedimentation of the rice wine in shelf life, comprising the following steps: original wine liquid clearing, freezing, heat preserving, filtering, encapsulating and sealing, sterilizing and packing; in the freezing process, the original wine is refrigerated through a liquid quick cooler, the wine flow is adjusted to ensure that the outlet temperature of the wine reaches minus 3 to minus 6 DEG C before entering a stainless steel insulation barrel for heat preservation for 48 to 96 hours; the fine rice wine is filtered by a liquid cross-flow membrane bacteria removal and microfiltration system with the entrapped grain size of 0.1 to 0.2 mu m; then the fine rice wine is water-bathed and sterilized. The invention has the benefits that the sediment can be pre-removed by freezing and heat preserving for a certain period before filtration; the precursors of large-particle high polymer protein existing in the fine rice wine undergoing freezing and heat preserving can be removed by the microfiltration techniques; therefore, the rice wine prepared by the method in the invention is light in color, is clean, transparent and glossy; during the shelf life of the rice wine, only a slight trace of sediment exists at the bottoms of bottles or jars; the flavour of the rice wine is not changed fundamentally.

The invention discloses a method for detecting recombinant lentivirus titer on the basis of gag gene. The method comprises the following three parts: designing a primer of lentivirus gag gene, constructing a standard substance for detecting lentivirus and measuring titer by a fluorescent quantitative PCR method. The method is convenient to operate, and the detection result is accurate. As lentivirus gag gene codes protein precursor of p55 and the protein precursor undergoes protease cleavage to form nucleocapsid protein (p7), inner membrane protein (p17) and capsid protein (p24) of the virus, the protein coded by gag is necessary to virion maturation. The primer is designed with the gene gag which must be carried by the lentivirus, and recombinant lentivirus titer is detected by fluorescent quantitative PCR. In comparison with the prior art, the detection primer for real-time quantitative PCR is designed in the gag area of lentiviral vector. Therefore, the detection is not dependent on an exogenous gene and is suitable for lentivirus of non-reporter gene vector, and the application range is wider.

This invention is in the field of pharmaceuticals, health supplements and chemical industries. In particular, this invention relates a herbal composition that compensates the A[beta] increasing effects of existing treatment, and on the regulatory processing of amyloid-[beta] protein precursor (APP), therefore presenting a significantly more potent treatment for neurodegenerative diseases that does not associate with any [beta]-amyloid increasing effect.

The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein precursor domain linked together via a linker sequence. The delivery domain is a protein capable of facilitating entry to a target cells via the endocytotic pathway, such as transferrin. The protein precursor is a prohormone or a profactor, such as proinsulin. Methods of this invention include the steps of selecting a protein suitable as the delivery domain, constructing a vector to encode the fusion protein, and expressing the fusion protein in a suitable expression host. Also disclosed is a method for targeted-delivery of prodrugs to livers and a method of reducing hepatic glucose production.

The invention discloses a circulating operation method which can be independently used for protein renaturation or used as guiding operation of protein renaturation. The method comprises the following steps: (1) adding a sample to be subjected to renaturation into a denaturation liquor for dissolving; (2) gradually separating out a denaturing agent from the liquor in a low-temperature environment, wherein in a micro level, denaturation salinity smooth decent gradient is generated at the molecular level; and gradually forming a renaturation and / or quasi-renaturation state protein precursor in the liquor, wherein along with separation by crystallization of the denaturing agent, the volume of the liquor is reduced, and the protein concentration is greatly increased; (3) separating a renaturation and / or quasi-renaturation state protein precursor; (4) dissolving crystal of the denaturing agent separated out in step (2) and the solution of the renaturation protein and / or quasi-renaturation state protein precursor separated out in step (3), and returning to the state of step (1), thus completing one production cycle. Various working media can be flexibly adjusted according to conditions. The method can be used for efficiently preparing a renaturation and / or quasi-renaturation state protein precursor.

This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein precursor domain linked together via a linker sequence. The delivery domain is a protein capable of facilitating entry to a target cells via the endocytotic pathway, such as transferrin. The protein precursor is a prohormone or a profactor, such as proinsulin. Methods of this invention include the steps of selecting a protein suitable as the delivery domain, constructing a vector to encode the fusion protein, and expressing the fusion protein in a suitable expression host.

The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein precursor domain linked together via a linker sequence. The delivery domain is a protein capable of facilitating entry to a target cells via the endocytotic pathway, such as transferrin. The protein precursor is a prohormone or a profactor, such as proinsulin. Methods of this invention include the steps of selecting a protein suitable as the delivery domain, constructing a vector to encode the fusion protein, and expressing the fusion protein in a suitable expression host. Also disclosed is a method for targeted-delivery of prodrugs to livers and a method of reducing hepatic glucose production.

The present invention is directed to, inter alia, a chimeric polynucleotide made up of a first polynucleotide encoding a specific cell predominantly expressed protein precursor and a second polynucleotide encoding a modulating-peptide. Further provided are methods for specific delivery of small modulating peptides to specific cells. Also provided are methods for treating cell-specific-associated diseases, including but not limited to, muscular, neural, hepatic and pancreatic disease, in a subject in need thereof.

Variants of amyloid [beta]-protein precursor inhibitor domain (A PPI), effective in inhibiting mesotrypsin and / or kallikrein-6, and composition comprising same, are provided. Further, methods of use of the peptides or composition, including, but not limited to treatment of cancer are provided.

The invention discloses a silkworm polypeptide function research method and application thereof. The method comprises the following steps of knocking out the gene of in-vivo encoded polypeptide firstly and then responding to phenotypic changes emerging due to gene knockout through the living body injection and supplement of the polypeptide via utilizing the characteristic that the polypeptide is carried by body fluid, so that the acting polypeptide is screened out, the functions of the polypeptide are determined as well, and particularly, the method has a very good effect on the polypeptide function research in which a protein precursor can be cut to form multiple kinds of polypeptide.

Various nucleic acids and proteins have been identified by differential hybridization methods as useful as markers for diagnosing kidney damage. The identified marker proteins include (I) androgen related protein, SON protein, FUSE binding Protein 1, claudin10, heat shock protein, phospho triesterase related protein, ubiquitin protein ligase Nedd-4, and Ac39 / physophilin, and (II) disabled-2 p96, palmitylated serine / threonine kinase, tumor differentially expressed 1 protein, cytochrome oxidase III, TLH 39 protein precursor, hydroxysteroid dehydrogenase 4 delta <5>-3 beta, and glutathione peroxidase III. The proteins of group (I), and antagonists of the proteins of group (II), are useful for protecting mammals against kidney damage.

The present invention relates to a method of modulating synaptic growth or plasticity by increasing the expression of genes found to be induced by BNDF. Such genes include c-fos proto-oncogene, early growth response protein 1, activity-regulated cytoskeletal associated, fos-related antigen 2, G1 / S-specific cyclin D1, voltagegated potassium channel protein, sodium channel beta 1 subunit, secretogranin II precursor, somatostatin receptor 4, transmembrane receptor UNC5 homology, neuropeptide Y, VGF protein precursor and protein-tyrosine phosphatase 1B. Methods of identifying agents which modulate the expression of these genes and the use of such agents for treating a disease or condition associated with damaged or diseased synapses are also provided.

The invention provides applications of beta-lactamase or peptide of which the identity is at least 20% with a beta-lactamase amino acid sequence as leading peptide in improving functional protein folding. One or more of resectable amino acid residues in a leader sequence used in the invention are same with one or more resectable amino acid residues of an isolated leader sequence and a to-be-folded protein precursor, which is good for resecting leader sequence segments after folding, thus the purification steps at the down stream can be simplified, and also the leader protein provided by the invention can improve the folding of functional protein.